1. Home
  2. REPL vs NPFD Comparison

REPL vs NPFD Comparison

Compare REPL & NPFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • NPFD
  • Stock Information
  • Founded
  • REPL 2015
  • NPFD 2021
  • Country
  • REPL United States
  • NPFD United States
  • Employees
  • REPL N/A
  • NPFD N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • NPFD Trusts Except Educational Religious and Charitable
  • Sector
  • REPL Health Care
  • NPFD Finance
  • Exchange
  • REPL Nasdaq
  • NPFD Nasdaq
  • Market Cap
  • REPL 547.0M
  • NPFD 480.1M
  • IPO Year
  • REPL 2018
  • NPFD N/A
  • Fundamental
  • Price
  • REPL $10.07
  • NPFD $19.84
  • Analyst Decision
  • REPL Buy
  • NPFD
  • Analyst Count
  • REPL 9
  • NPFD 0
  • Target Price
  • REPL $10.88
  • NPFD N/A
  • AVG Volume (30 Days)
  • REPL 8.8M
  • NPFD 64.7K
  • Earning Date
  • REPL 11-07-2025
  • NPFD 01-01-0001
  • Dividend Yield
  • REPL N/A
  • NPFD 6.28%
  • EPS Growth
  • REPL N/A
  • NPFD N/A
  • EPS
  • REPL N/A
  • NPFD N/A
  • Revenue
  • REPL N/A
  • NPFD N/A
  • Revenue This Year
  • REPL N/A
  • NPFD N/A
  • Revenue Next Year
  • REPL N/A
  • NPFD N/A
  • P/E Ratio
  • REPL N/A
  • NPFD N/A
  • Revenue Growth
  • REPL N/A
  • NPFD N/A
  • 52 Week Low
  • REPL $2.68
  • NPFD $14.50
  • 52 Week High
  • REPL $17.00
  • NPFD $18.07
  • Technical
  • Relative Strength Index (RSI)
  • REPL 75.32
  • NPFD 53.19
  • Support Level
  • REPL $7.69
  • NPFD $19.63
  • Resistance Level
  • REPL $10.85
  • NPFD $20.00
  • Average True Range (ATR)
  • REPL 0.67
  • NPFD 0.21
  • MACD
  • REPL 0.48
  • NPFD -0.02
  • Stochastic Oscillator
  • REPL 88.10
  • NPFD 44.39

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About NPFD Nuveen Variable Rate Preferred & Income Fund

Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.

Share on Social Networks: